Drugging the undruggable RAS: Mission Possible?

被引:0
|
作者
Adrienne D. Cox
Stephen W. Fesik
Alec C. Kimmelman
Ji Luo
Channing J. Der
机构
[1] Lineberger Comprehensive Cancer Center,
[2] University of North Carolina at Chapel Hill,undefined
[3] Vanderbilt University School of Medicine,undefined
[4] Dana-Farber Cancer Institute,undefined
[5] National Cancer Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Attempts to target RAS pharmaceutically have not yet yielded small molecules with sufficient potency and drug-like characteristics to be useful, but additional approaches are underway.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.Inhibitors of RAS effector signalling are currently centred on the RAF–MEK–ERK and PI3K–AKT–TOR pathways, with many inhibitors of components of these two pathways under clinical evaluation. The less well-studied effector pathways that lead to activation of RAL and RAC small GTPases are also promising targets.Despite some setbacks owing to issues of reproducibility, functional screens for synthetic lethal interactors with oncogenic RAS remain an attractive approach to identify novel drug targets for RAS-driven cancers.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.Inhibitors of RAS membrane interaction and subcellular localization remain attractive targets for therapeutic intervention. In this regard, recent discoveries of functionally relevant post-translational modifications of RAS, such as phosphorylation and ubiquitylation, suggest new opportunities to block RAS function.RAS-driven cancers become efficient scavengers of nutrients and may rely on pathways such as autophagy and macropinocytosis. Furthermore, oncogenic KRAS has a crucial role in altering tumour metabolism, including rewiring of both glucose- and glutamine-dependent metabolic pathways. These alterations could provide the opportunity for novel therapeutic interventions.
引用
收藏
页码:828 / 851
页数:23
相关论文
共 50 条
  • [31] Drugging the undruggable: Transcription therapy for cancer
    Yan, Chunhong
    Higgins, Paul J.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2013, 1835 (01): : 76 - 85
  • [32] Drugging "undruggable" transcription factor drivers in cancer
    Bushweller, John
    CANCER RESEARCH, 2016, 76
  • [33] Drugging undruggable kras: will myc do the trick?
    Der, Channing J.
    CANCER RESEARCH, 2016, 76
  • [34] DRUGGING "UNDRUGGABLE" TARGETS USING STAPLED PEPTIDES
    Verdine, G.
    BIOPOLYMERS, 2009, 92 (04) : 296 - 296
  • [35] Drugging ''undruggable" neurodegenerative disease targets with small molecules
    Lu, Junmei
    Li, Zhaoyang
    Gitler, Aaron D.
    Lu, Boxun
    SCIENCE BULLETIN, 2023, 68 (16) : 1715 - 1718
  • [36] Targeting allosteric regulatory modules in oncoproteins: "Drugging the Undruggable"
    Hantschel, Oliver
    Grebien, Florian
    Superti-Furga, Giulio
    ONCOTARGET, 2011, 2 (11) : 828 - 829
  • [37] Drugging the undruggable proteins in cancer: A systems biology approach
    Pathmanathan, Shivanthy
    Grozavu, Ingrid
    Lyakisheva, Anna
    Stagljar, Igor
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2022, 66
  • [38] Targeted Covalent Modification Strategies for Drugging the Undruggable Targets
    Tamura, Tomonori
    Kawano, Masaharu
    Hamachi, Itaru
    CHEMICAL REVIEWS, 2025, 125 (02) : 1191 - 1253
  • [39] Drugging the Undruggable Trypanosoma brucei Monothiol Glutaredoxin 1
    Favaro, Annagiulia
    Bolcato, Giovanni
    Comini, Marcelo A. A.
    Moro, Stefano
    Bellanda, Massimo
    Sturlese, Mattia
    MOLECULES, 2023, 28 (03):
  • [40] Drugging the undruggable: Ross Cagan interviews Kevan Shokat
    Cagan, Ross
    Shokat, Kevan
    DISEASE MODELS & MECHANISMS, 2022, 15 (02)